Seasonal Influenza Therapeutics Asia-Pacific Markets Forecast To Growing Rapidly at CAGE Of 4.7% To 2022

Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies report analysis shows that the R&D pipeline for seasonal influenza vaccines comprises a high number of vaccines in early-stage development, many of which are new formulations or those that have been developed using the cell culture method. Late-stage vaccines are either quadrivalent vaccines or pediatric versions of those that have already been approved. Research expects that quadrivalent seasonal influenza vaccines will replace their trivalent vaccines forerunner by the end of the forecast period.

Get Complete Report on Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies Report spread across 108 pages available at: http://www.reportsnreports.com/reports/839646-seasonal-influenza-therapeutics-in-asia-pacific-markets-to-2022-growth-driven-by-rising-elderly-population-growing-awareness-and-launch-of-quadrivalent-therapies.html

The seasonal influenza Asia-Pacific market will be valued at $1.71 billion in 2022, growing from $1.24 billion in 2015 at a CAGR of 4.7%.In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. APAC region is an attractive market for seasonal influenza vaccine manufacturers.

Key Questions Answered On Seasonal Influenza Therapeutics Markets In This Report Are:

  • Will the drugs under development fulfill the unmet needs of the seasonal influenza market?
  • Do quadrivalent therapies show continuous growth, and are they facing any competition from trivalent therapies?
  • How will available therapies be affected by upcoming pipeline therapies?
  • Which molecular targets appear most frequently in the pipeline?
  • Will the pipeline drugs fulfill the unmet needs of seasonal influenza market?
  • How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
  • What barriers limit the uptake of premium-priced vaccines in the assessed countries?
  • What factors are most likely to drive the market in these countries?

Request Sample Report At: http://www.reportsnreports.com/contacts/requestsample.aspx?name=839646

Table of Contents:

  • Influenza Testing Methods 16
  • Influenza Vaccination Recommendation Committees by Country
  • Seasonal Influenza Therapeutics Market, Asia-Pacific, Most Administered Influenza Vaccines by Country
  • Available Antiviral Drugs for Seasonal Influenza
  • Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
  • Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
  • Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
  • Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Phase II, 2016
  • Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
  • Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Pre-registration Phase, 2016
  • Seasonal influenza Therapeutics Market, Asia-Pacific, Market Forecast, 2015-2022
  • Seasonal Influenza Therapeutics Market, India, Market Forecast, 2015-2022
  • Seasonal Influenza Therapeutics Market, China, Market Forecast, 2015-2022
  • Seasonal Influenza Therapeutics Market, Australia, Market Forecast, 2015-2022 9
  • Seasonal Influenza Therapeutics Market, South Korea, Market Forecast, 2015-2022
  • Seasonal Influenza Therapeutics Market, Japan, Market Forecast, 2015-2022

 

Get This Report: http://www.reportsnreports.com/purchase.aspx?name=839646

Key Highlights:

The seasonal influenza Asia-Pacific market will be valued at $1.71 billion in 2022, growing from $1.24 billion in 2015 at a CAGR of 4.7%.

Trivalent and quadrivalent vaccines dominate the seasonal influenza market, but unmet needs exist in terms of safety and efficacy.

  • Will the drugs under development fulfill the unmet needs of the seasonal influenza market?
  • Do quadrivalent therapies show continuous growth, and are they facing any competition from trivalent therapies?
  • How will available therapies be affected by upcoming pipeline therapies?

The pipeline contains a range of molecule types and molecular targets, including those that are well established in seasonal influenza.

  • Which molecular targets appear most frequently in the pipeline?
  • Will the pipeline drugs fulfill the unmet needs of seasonal influenza market?

Market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the emergence of quadrivalent therapies.

  • How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?

Various drivers and barriers will influence the market over the forecast period.

  • What barriers limit the uptake of premium-priced vaccines in the assessed countries?
  • What factors are most likely to drive the market in these countries?

Reasons to Buy

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the seasonal influenza market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
  • Analyze the seasonal influenza pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict seasonal influenza market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as analysis of the contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the seasonal influenza deals landscape by analyzing trends in licensing and co-development deals.

About Us:

Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

%d bloggers like this: